cabergoline / Generic mfg. - LARVOL DELTA

LISTA3: A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Stanford University | Trial completion date: Jul 2026 ➔ Jul 2027 | Initiation date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Trial initiation date • Trial primary completion date

Cerebrospinal fluid fistula following dopamine agonist therapy in giant prolactinomas: A case series and review of the literature. (PubMed, Neurol Neurochir Pol) - "Skull base erosion and rapid tumor shrinkage are major contributors. Our findings support early recognition, dose titration of DA therapy, close radiological follow-up, and timely surgical intervention. Further studies are needed to define risk stratification and evidence-based treatment protocols."

Journal • CNS Disorders • Infectious Disease • Oncology

Long-term survival in a patient with metastatic prolactinoma: A 12-year follow-up (SNO 2025) - "Temozolomide (TMZ) has previously been shown to be effective in treating these rare cases once first-line medical, surgical and radiation therapies have failed...The patient underwent proton therapy and increased cabergoline dosing...As of early 2025, imaging has shown no new metastatic lesions and stabilization of the lumbar lesion, and lab work has demonstrated stable prolactin levels. Despite an initially poor prognosis, the patient has survived for over a decade since the diagnosis of prolactinoma and more than four years since the metastatic spread."

Clinical • Metastases • Neuroendocrine Tumor • Pituitary Gland Carcinoma • Solid Tumor

Sex differences in lactotroph adenomas: Tumor size and prolactin predict postoperative outcomes (SNO 2025) - "Lactotroph adenomas in males had significantly greater preoperative prolactin levels and tumor size, both predictive of incomplete resection and need for continued postoperative cabergoline. Our data represent further evidence that male lactotrophs are more aggressive and treatment-refractory compared to female lactotrophs."

Oncology • Pituitary Gland Carcinoma

Hyperprolactinemia and migraine-like headache: A case report and literature review (EHF-EHC 2025) - "She was treated with bromocriptine for three months, achieving complete headache resolution...Repeat MRI showed a pituitary microadenoma, and cabergoline was reinitiated, with significant headache improvement...Eletriptan was prescribed for acute attacks...Dopamine agonists may relieve symptoms, even without tumor shrinkage, indicating a hormonal component. Pituitary hormones like PRL and hypothalamic peptides such as oxytocin may underlie sex differences in migraine.Endocrine evaluation is advised in refractory or atypical headache cases."

Case report • Clinical • Review • CNS Disorders • Endocrine Disorders • Gynecology • Migraine • Pain

PCOS OID: Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS (clinicaltrials.gov) - P=N/A | N=72 | Recruiting | Sponsor: Mst.Sumyara Khatun

New trial • Infertility • Polycystic Ovary Syndrome

Real-life data on pasireotide in monotherapy or combined in active Cushing's disease. (PubMed, Front Endocrinol (Lausanne)) - "This is a retrospective monocentric study evaluating the real-life efficacy and safety of pasireotide alone or when combined with cabergoline or metyrapone. This is the first study to report metyrapone add-on to pasireotide, but larger studies are needed to further investigate this association. Pasireotide surely worsens glucose homeostasis, but its positive effects, alone or combined, on blood pressure, lipid profile, and body weight justify its use under careful hyperglycemia management."

Journal • Monotherapy • Retrospective data • Cardiovascular • Cushing’s Disease • Diabetes • Endocrine Disorders

Giant Prolactinoma Resistant to High-Dose Cabergoline in a Young Male Lost to Follow-Up. (PubMed, Cureus) - "Discussions around medical, surgical, and radiotherapeutic management are being raised in light of this cabergoline resistance and placement. The case overall highlights the complexities of managing giant, dopamine agonist-resistant prolactinomas, especially in the setting of delayed follow-up, incomplete biochemical control, and neuropsychiatric side effects."

Journal • Acromegaly • Cushing’s Disease • Endocrine Disorders • Oncology • Pain • Pituitary Gland Carcinoma • Psychiatry

Case Report: Management of a pregnancy complicated by a symptomatic macroprolactinoma. (PubMed, Front Med (Lausanne)) - "Dopamine agonists remain the cornerstone of therapy and are generally safe during early pregnancy. Meticulous anesthetic planning is essential to optimize maternal and fetal outcomes."

Journal • Anesthesia • Gynecology • Hematological Disorders • Infertility • Obstetrics • Oncology • Pituitary Gland Carcinoma • Sexual Disorders

Integrating axis quantitative trait loci looks beyond cell types and offers insights into brain-related traits. (PubMed, Nat Commun) - "Analyzing single-cell expression quantitative trait loci with cortex bulk data from MetaBrain using BASIC identified 5644 additional gene with quantitative trait loci (74.5%), equivalent to a 76.8% increase in sample size. Integrating axis-quantitative trait loci with 12 brain-related traits improved colocalization by 53.5% versus single-cell studies and 111% versus bulk studies, revealing risk genes such as DEDD for Alzheimer's disease and drug candidates including cabergoline."

Journal • Alzheimer's Disease • CNS Disorders • DEDD

Therapeutic challenges of giant invasive cystic macroprolactinoma. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Postoperatively, despite sequential treatment with bromocriptine and cabergoline (maximum approved dose of 3 mg/week), prolactin levels failed to normalize. Dopamine agonists remain the first-line therapy for both giant and cystic prolactinomas. Early surgical intervention is indicated for vision-threatening conditions or in cases of dopamine agonist resistance."

Journal • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • PRL

Gestational Gigantomastia: A Century of Evidence with a New Case. (PubMed, Plast Reconstr Surg Glob Open) - "First-line medical therapy (bromocriptine, cabergoline, or norethindrone) achieved partial arrest in approximately 35% of trials; definitive control required surgery in 57% (reduction mammaplasty 29%, mastectomy 28%). Early recognition, prompt endocrine modulation, and timely, staged surgery are critical. We provide the largest curated dataset to date, quantify the mortality risk, and propose a stepwise management algorithm to guide multidisciplinary teams confronting this formidable obstetric challenge."

Journal • Hematological Disorders • Infectious Disease • Obstetrics • Septic Shock

Use of Pasireotide in Acromegaly: Clinical Experiences From a Series of Patients in Qatar. (PubMed, Case Rep Endocrinol) - "Patient 2, 48-year-old male with a significant macroadenoma and prior cabergoline treatment, achieved partial biochemical control. Four out of these five patients showed reduction in tumour size. This case series corroborates the findings from previous studies, adding insight into treatment challenges and benefits experienced by this heterogeneous group of patients on pasireotide."

Journal • Acromegaly • Diabetes • Endocrine Disorders • Metabolic Disorders • Oncology • Pituitary Gland Carcinoma • Type 2 Diabetes Mellitus • IGF1 • SSTR

Galactorrhea after Breast Augmentation with Mastopexy: Case Reports and Literature Review. (PubMed, Arch Plast Surg) - "In two cases, galactorrhea was treated with oral dopaminergic medication cabergoline, with a good response to the therapy...In conclusion, galactorrhea is a rare but significant complication of any mammaplasty surgery. Untreated secretion may lead to severe complications; however, early recognition and treatment may lead to good results and patient satisfaction."

Journal • Aesthetic Medicine • Pain

The Trigger Effect of GnRH Agonist Repeated Dose on Intracytoplasmic Sperm Injection Outcomes: A Randomized Single-Blinded Clinical Trial. (PubMed, Reprod Med Biol) - "There was no significant difference regarding premature ovulation, use of Cabergoline, chemical and clinical pregnancy, miscarriage, and live birth rates between the 2 study groups. It seems that the administration of the second dose of GnRHa 12 h after the first dose leads to better oocyte maturation and higher quality embryos. IRCT20081007001306N11; https://irct.behdasht.gov.ir/trial/60387."

Clinical • Journal • Gynecology • Infertility • Sexual Disorders

Long-term survival in a patient with metastatic prolactinoma: A 12-year follow-up (WFNOS 2025) - "Temozolomide (TMZ) has previously been shown to be effective in treating these rare cases once first-line medical, surgical and radiation therapies have failed...The patient underwent proton therapy and increased cabergoline dosing...As of early 2025, imaging has shown no new metastatic lesions and stabilization of the lumbar lesion, and lab work has demonstrated stable prolactin levels. Despite an initially poor prognosis, the patient has survived for over a decade since the diagnosis of prolactinoma and more than four years since the metastatic spread."

Clinical • Metastases • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor

Sex differences in lactotroph adenomas: Tumor size and prolactin predict postoperative outcomes (WFNOS 2025) - "Lactotroph adenomas in males had significantly greater preoperative prolactin levels and tumor size, both predictive of incomplete resection and need for continued postoperative cabergoline. Our data represent further evidence that male lactotrophs are more aggressive and treatment-refractory compared to female lactotrophs."

Pituitary Gland Carcinoma • Solid Tumor

PROTECT: Cabergoline for Episodic Migraine (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Aarhus University Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Migraine • Pain

A Study on Bioequivalence of Cabergoline Tablets in Human Body (clinicaltrials.gov) - P1 | N=72 | Active, not recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed

Histopathological evaluation of dopamine receptor D2 expression in symptomatic gonadotroph pituitary neuroendocrine tumors: a case series including a rare metastatic case responsive to a dopamine agonist. (PubMed, Brain Tumor Pathol) - "In a rare case of metastatic Gn-PitNET, cabergoline was associated with tumor stability and hormone control. Further studies may clarify whether DRD2 expression can help predict DA responsiveness in refractory tumors.(200/200 words)."

Journal • Neuroendocrine Tumor • Oncology • Pituitary Gland Carcinoma • Solid Tumor • DRD2

Clinical practice considerations on cabergoline in the treatment of pituitary prolactinoma (PubMed, Zhonghua Yi Xue Za Zhi) - "Cabergoline, a selective D2 receptor agonist with high receptor affinity and long-acting properties, is recommended as a first-line treatment in international guidelines for prolactinoma management.Based on the 2014 edition, the "Consensus on the diagnosis and treatment of pituitary prolactinoma (2025 edition)" has made important updates to the treatment recommendations for cabergoline, mainly including: For patients with bromocriptine resistance, if cabergoline is available, switching to cabergoline is recommended as the first choice; For patients receiving long-term, high-dose cabergoline treatment, regular echocardiogram monitoring is recommended to assess the condition of heart valves. However, since cabergoline has not yet been marketed in Chinese mainland, the practical clinical experience with this drug in the domestic setting remains relatively limited, and there is a lack of systematic summary of local data. Endocrinologists need to pay special..."

Journal • Cardiovascular • Neuroendocrine Tumor • Oncology • Solid Tumor

Approach to the Patient with Dopamine-Resistant Microprolactinoma. (PubMed, J Clin Endocrinol Metab) - "Other conditions in which hyperprolactinemia could be implicated, such as metabolic parameters, osteoporosis, and breast cancer risk are also discussed. Understanding the mechanisms of DA resistance can lead to the opening of new treatment strategies."

Journal • Breast Cancer • Endocrine Disorders • Infertility • Oncology • Pituitary Gland Carcinoma • Rheumatology • Sexual Disorders • Solid Tumor • Women's Health

Comparative study between calcium gluconate with diosmin, cabergoline, and cabergoline with diosmin in prevention of ovarian hyperstimulation syndrome in high-risk women undergoing intracytoplasmic sperm injection (ICSI) procedures. (PubMed, Front Pharmacol) - P=N/A | "This combination did not impact miscarriage, pregnancy rate, or the likelihood of multiple pregnancy. identifier NCT06333691."

Journal

Cabergoline-Induced Gambling Causing Increased Adrenal Crisis Episodes. (PubMed, JCEM Case Rep) - "Our case emphasizes the need for routine behavioral screening in patients treated with dopamine agonists. Early identification and discontinuation or dose reductions of dopamine agonists is recommended to allow for ICD resolution and consequently, reducing the risk of exacerbating adrenal crisis episodes."

Journal • Acromegaly • Endocrine Disorders • Oncology • Psychiatry

Accessory breast granulomatous mastitis: A case report and mini-review of the literature. (PubMed, Med Int (Lond)) - "The diagnosis was chronic mastitis, and she was treated with oral corticosteroids, amoxicillin, cabergoline and analgesics. On the whole, the present study demonstrates that accessory breast tissue can develop GM. While corticosteroids may provide favorable short-term results, they do not necessarily prevent recurrence, whereas surgical management may provide more durable long-term outcomes."

Journal • Inflammation • Pain